Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia

Journal of Urology

Volumn 190, Issue 1, 2013, Pages 187-193

  Fwu, Chyng Wen ^a   Eggers, Paul W ^b   Kaplan, Steven A ^c   Kirkali, Ziya ^b   Lee, Jeannette Y ^d   Kusek, John W ^b  

^a SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

doxazosin; finasteride; lower urinary tract symptoms; prostatic hyperplasia; quality of life

Indexed keywords

DOXAZOSIN; FINASTERIDE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FINASTERIDE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME; TREATMENT OUTCOME;

EID: 84878892469     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.01.061     Document Type: Article

References (26)

1. J.T. Wei, E. Calhoun, S.J. Jacobsen Urologic Diseases in America Project: benign prostatic hyperplasia J Urol 179 suppl. 2008 S75
2. J.K. Parsons Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors Curr Bladder Dysfunct Rep 5 2010 212
3. M.J. Barry Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia Urology 58 2001 25
4. D.S. Elterman, J. Barkin, S.A. Kaplan Optimizing the management of benign prostatic hyperplasia Ther Adv Urol 4 2012 77
5. J.D. McConnell, C.G. Roehrborn, O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387
6. C.G. Roehrborn, P. Siami, J. Barkin The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study J Urol 179 2008 616
7. M.J. Barry, W.O. Williford, Y. Chang Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154 1995 1770
8. J.E. Batista-Miranda, M.D. Diez, P.A. Bertran Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions Pharmacoeconomics 19 2001 1079
9. R.O. Fourcade, F. Lacoin, M. Rouprêt Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia World J Urol 30 2012 419
10. H. Lepor, W.O. Williford, M.J. Barry The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group J Urol 160 1998 1358
11. F. Montorsi, T. Henkel, A. Geboers Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study Int J Clin Pract 64 2010 1042
12. J.W. Kusek, A. Ahrens, P.K. Burrows Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia Urology 59 2002 63
13. O.M. Bautista, J.W. Kusek, L.M. Nyberg Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial Control Clin Trials 24 2003 224
14. J.E. Ware, K.K. Snow, M. Kosinski SF-36 Health Survey Manual and Interpretation Guide 1993 The Health Institute, New England Medical Center Boston
15. M.J. Barry, F.J. Fowler Jr, M.P. O'Leary The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1992 1549
16. M.J. Barry, F.J. Fowler Jr, M.P. O'Leary Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association Med Care 33 1995 AS145
17. M.J. Barry, J. Adolfsson, J.E. Batista Measuring symptoms and health impact of benign prostatic hyperplasia and its treatments L. Denis, K. Griffiths, S. Khoury, 4th International Consultation on Benign Prostatic Hyperplasia 1998 Plymbridge Distributors, Ltd. Plymouth, UK 265
18. J. Cohen Statistical Power Analysis for the Behavioral Sciences 2nd ed. 1988 Lawrence Erlbaum Associates, Inc. Hillsdale, New Jersey
19. J.M. Lachin Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations Stat Med 11 1992 1151
20. M.J. Barry, A. Cantor, C.G. Roehrborn Relationships among participant International Prostate Symptom Score and Benign Prostatic Hyperplasia Impact Index changes and global ratings of change in a trial of phytotherapy for men with lower urinary tract symptoms J Urol 189 2013 987
21. A. Carter, H. Sells, M. Speakman Quality of life changes following KTP/Nd:YAG laser treatment of the prostate and TURP Eur Urol 36 1999 92
22. R.O. Roberts, S.J. Jacobsen, T. Rhodes Natural history of prostatism: impaired health states in men with lower urinary tract symptoms J Urol 157 1997 1711
23. G. Welch, K. Weinger, M.J. Barry Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study Urology 59 2002 245
24. G. Engström, L. Henningsohn, M.L. Walker-Engström Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire Scand J Urol Nephrol 40 2006 485
25. C.A. Byrnes, A.S. Morton, C.L. Liss Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar Clin Ther 17 1995 956
26. J.L. Tenover, G.A. Pagano, A.S. Morton Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group Clin Ther 19 1997 243